Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is directly supported by the FDA label’s boxed warning and Warnings and Precautions section for Huntington’s disease patients, including monitoring and risk statements.
Category Scores
Accurate Statements
Risk of depression and suicidal ideation/behavior in patients with Huntington’s disease treated with INGREZZA/INGREZZA SPRINKLE (VMAT2 inhibitors).
Supported by the Boxed Warning and Warnings and Precautions (5.1) stating VMAT2 inhibitors including INGREZZA/INGREZZA SPRINKLE can increase risk of depression and suicidal thoughts/behavior in patients with Huntington’s disease.
Label supports increased risk and includes clinical trial incidence data (depression/depressed mood 4.7% vs 1.6% on INGREZZA vs placebo).
Consistent with provided label excerpts from 6.1 (Psychiatric Disorders: Depression, depressed mood 4.7% vs 1.6%).
Unsupported Statements
Contradictions
Important Omissions
The AI response does not include the label’s specific monitoring/discontinuation guidance (e.g., observe for new/worsening depression/suicidal ideation/behaviors; consider discontinuing if reactions occur and do not resolve).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claim is consistent with the boxed warning and is framed as a risk statement; it does not provide dosing or treatment instructions that could create direct safety harm.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The claim is correct but lacks the label’s detailed monitoring/discontinuation instructions.
Suggested Improvement
When restating the boxed warning, include that patients should be observed for new or worsening depression and suicidal ideation/behaviors, and consider discontinuing if reactions occur and do not resolve.